A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: A phase I/II study

European Journal of Cancer

Volumn 47, Issue 7, 2011, Pages 1037-1045

  Villanueva, C ^a   Awada, A ^b   Campone, M ^c   Machiels, J P ^d   Besse, T ^b   Magherini, E ^e   Dubin, F ^e   Semiond, D ^e   Pivot, X ^a  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^b JULES BORDET INSTITUTE   (Belgium)

^c CENTRE RENÉ GAUDUCHEAU   (France)

^d CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^e SANOFI   (France)

Author keywords

Chemotherapy; Metastatic breast cancer; Resistance; Taxane; Taxoid; XRP6258

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CABAZITAXEL; CAPECITABINE; TAXANE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASTHENIA; BREAST CANCER; BREAST METASTASIS; CANCER GROWTH; CLINICAL ARTICLE; COLITIS; CONSTIPATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HAND FOOT SYNDROME; HEADACHE; HUMAN; INFECTION; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; NEUTROPENIC COLITIS; NEUTROPENIC INFECTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BREAST NEOPLASMS; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; TAXOIDS; TREATMENT OUTCOME;

EID: 79953713649     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.01.001     Document Type: Article

References (29)

1. Cardoso F, Bedard PL, Winer EP, et al. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst 2009;101:1174-81.
2. NCCN Clinical Practice Guidelines in Oncology - Breast Cancer V.2.2010. 〈http://www.nccn.org/professionals/physician-gls/PDF/breast.pdf〉. Accessed August 31, 2010.
3. Beslija S, Bonneterre J, Burstein HJ, et al. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 2009;20:1771-85.
4. Dufresne A, Pivot X, Tournigand C, et al. Impact of chemotherapy beyond the first line in patients with metastatic breast cancer. Breast Cancer Res Treat 2008;107:275-9. (Pubitemid 350265698)
5. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002;20:2812-23. (Pubitemid 34651510)
6. Cabral F. Factors determining cellular mechanisms of resistance to antimitotic drugs. Drug Resist Updat 2001;4:3-8. (Pubitemid 32267819)
7. Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: Microtubule dynamics, drug transport, and cell death. J Clin Oncol 1999;17:1061-70. (Pubitemid 29109340)
8. Bissery MC, Bouchard H, Riou JF, et al. Preclinical evaluation of TXD258, a new taxoid. 91st Annual Meeting of the American Association for Cancer Research, San Fancisco, April 1-5, 1364, 41, 2000.
9. Bissery MC. Preclinical evaluation of new taxoids. Curr Pharm Des 2001;7:1251-7.
10. Vrignaud P, Lejeune P, Chaplin D, et al. In vivo efficacy of TXD258, a new taxoid, against human tumor xenografts. 91st Annual Meeting of the American Association for Cancer Research, San Fancisco, April 1-5, #1365, 41, 2000.
11. Dykes DJ, Sarsat JP, Bissery MC. Efficacy evaluation of TXD258, a taxoid compound, against orthotopic and subcutaneous glioblastomas. 91st Annual Meeting of the American Association for Cancer Research, San Fancisco, April 1-5, #1916, 41, 2000.
12. Pivot X, Asmar L, Buzdar AU, et al. A unified definition of clinical anthracycline resistance breast cancer. Br J Cancer 2000;82:529-34. (Pubitemid 30085185)
13. Pivot X, Koralewski P, Hidalgo JL, et al. A multicenter phase II study of XRP6258 administered as a 1 - h i v infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 2008;19:1547-52.
14. Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999;17:485-93. (Pubitemid 29075232)
15. Sawada N, Ishikawa T, Fukase Y, et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin page Cancer Res 1998;4:1013-9. (Pubitemid 28183404)
16. Fujimoto-Ouchi K, Tanaka Y, Tominaga T. Schedule dependency of antitumor activity in combination therapy with capecitabine/50-deoxy-5-fluorouridine and docetaxel in breast cancer models. Clin Cancer Res 2001;7:1079-86. (Pubitemid 32708748)
17. Nadella P, Shapiro C, Otterson GA, et al. Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies. J Clin Oncol 2002;20:2616-23. (Pubitemid 34575633)
18. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
20. Pivot X, Thierry-Vuillemin A, Villanueva C, et al. Response rates: a valuable signal of promising activity? Cancer J 2009;15:361-5.
21. Fumoleau P, Largillier R, Clippe C, et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 2004;40:536-42. (Pubitemid 38220770)
22. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007;25:3407-14. (Pubitemid 47310876)
23. Pivot X, Villanueva C, Chaigneau L, et al. Ixabepilone, a novel epothilone analog in the treatment of breast cancer. Expert Opin Investig Drugs 2008;17:593-9. (Pubitemid 351578176)
24. Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007;25:5210-7. (Pubitemid 350232252)
25. Reigner B, Blesch K,WeidekammE. Clinical pharmacokinetics of capecitabine. Clin. Pharmacokinet 2001;40:85-104. (Pubitemid 32242792)
26. Mita AC, Denis LJ, Rowinsky EK, et al. Phase I and pharmacokinetic study of RPR 116258A, a novel taxane derivative, administered as a 1-hour infusion every three weeks in patients with advanced solid tumors. Clin Cancer Res 2009;15:723-30.
27. Soepenberg O, Dumez H, Verweij J, et al. Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors. J Clin Oncol 2007;25:3753-8.
28. Pronk LC, Vasey P, Sparreboom A, et al. A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours. Br J Cancer 2000;83:22-9. (Pubitemid 30352712)
29. Chaigneau L, Royer B, Montange D, et al. Influence of capecitabine absorption on its metabolites pharmacokinetics: a bioequivalence study. Ann Oncol 2008;19:1980-1.